srf617
Generic: Perenostobart
srf617: sourced relationships with 1 company · 1 clinical trial tracked.
srf617 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect srf617 to SURF; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could srf617 → SURF affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Surface Oncology, Inc. (SURF) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Number of Participants With Response
Interventionalopen16 targetStarted 2022-01Completion 2023-049 sites · Canada, United StatesCoherus Oncology, Inc.
Frequently asked questions
Which companies have sourced relationships with srf617?
srf617 has dated SEC/FDA relationship records for Surface Oncology, Inc..
How many clinical trials involve srf617?
BioSniper tracks 1 clinical trial involving srf617.